Riskpilot← Back to searchSign inGet full accessAÏDA ONCOLOGY Aps
APSActiveCVR 42246468Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20215 employees
Revenue 2024
DKK -2,4M
+11% vs 2023
EBITDA margin
140.7%
-44% vs 2023
Equity ratio
-51.9%
Financial strength
Net profit 2024
DKK -2,6M
-11% vs 2023
| Revenue | DKK -2,4M | +11% |
| EBITDA | DKK -3,4M | -44% |
| Net profit | DKK -2,6M | -11% |
| Total assets | DKK 9,9M | +470% |
| Equity | DKK -5,1M | -104% |
| Employees | 5 | — |
Legal name
AÏDA ONCOLOGY Aps
CVR number
42246468
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23. marts 2021
Share capital
DKK 40.000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af den administrerende direktør i forening med 1 bestyrelsesmedlem, eller af alle bestyrelsesmedlemmer i forening
Company purpose
Virksomhedens formål er at udvikle og kommercialisere produkter og services relateret til behandling af kræft
Address
Ole Maaløes Vej 3
Phone
+4521701049
Email
uhb@buhloncology.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | -2.169 | -2.409 |
| Staff expenses | -0 | -0 | -191 | -979 |
| EBITDA | -5 | -179 | -2.360 | -3.388 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -5 | -179 | -2.360 | -3.388 |
| Net financials | 0 | -0 | -1 | -88 |
| Profit before tax | -5 | -180 | -2.360 | -3.477 |
| Tax | -0 | -0 | -0 | -863 |
| Net profit | -5 | -180 | -2.360 | -2.613 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 35 | 1 | 1.729 | 9.855 |
| Equity | 35 | -145 | -2.505 | -5.118 |
| Long-term debt | 0 | 0 | 4.000 | 14.304 |
| Short-term debt | 0 | 146 | 233 | 669 |
| Total debt | 0 | 146 | 4.233 | 14.973 |
EBITDA margin
-338826800.0%
This company
15.8%
Market median
-2144473518% vs market
20212024
Equity ratio
-51.9%
This company
38.2%
Market median
-236% vs market
20212024
Return on equity
-261342200.0%
This company
18.4%
Market median
-1420338143% vs market
20212024
Net profit margin
-261342200.0%
This company
8.1%
Market median
-3226447014% vs market
20212024
Asset turnover
-0.24×
This company
1.12×
Market median
-121% vs market
20212024
Debt / equity
2.93×
This company
0.62×
Market median
-373% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-03-23 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
UH Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
CF Management | Management | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BUHL KRONE HOLDING ApS | Company | 50.0% | 50.0% | 2021 |
| Individual | 25.0% | 25.0% | 2021 | |
Arrow Strategy Holding 2 ApS | Company | 15.0% | 15.0% | 2021 |
| Individual | 5.0% | 5.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AÏDA ONCOLOGY Aps also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulla Hald Buhl | Chief Executive Officer | 0 companies |
| Claus Frisenberg Pedersen | Management | 0 companies |
| Neil Goldsmith | Chairman | 0 companies |
| Peter Buhl | Board of Directors | 0 companies |